News
-
-
-
-
-
-
-
-
PRESS RELEASE
Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
Heidelberg Pharma granted orphan drug designation by FDA for its ATAC candidate HDP-101, targeting multiple myeloma. The designation provides significant benefits for the development and potential marketing of the drug -
-
PRESS RELEASE
Heidelberg Pharma announces financial figures and reports on successful business performance in 2023
Heidelberg Pharma AG announces financial figures and successful business performance in 2023, including efficacy data from HDP-101 clinical trial. New Management Board team and expansion of ADC technology platform
-
Revolutionizing Fire Camps: NUE's Sustainable Power Solutions Shine at USDA Technology & Development Center
-
Save A Train Continues to Innovate with Rail Enrichment
-
Cameron Ashley Building Products Opens Third Location in the Badger State
-
Event Tickets Center is Named Official Secondary Ticketing Reseller Partner for Most Valuable Promotions and the Historic Jake Paul vs. Mike Tyson Fight
-
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor CEO Connect
-
Amendment of the terms and conditions of the bond completed; Bondholders can convert bonds into shares
-
secunet Security Networks AG successfully holds Annual General Meeting – Broad approval for all proposed resolutions
-
TUI AG: Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
-
Fuller, Smith & Turner PLC: Transaction in own shares
-
AngloGold Ashanti US$9.0m (A$13.5m) Gold Farm-in Agreement
-
2024 Annual General Meeting: approval of all resolutions submitted to the Meeting
-
PR – ICADE – Success of the cash tender offer for a total amount of €350 million
-
AMOEBA: ORDINARY AND EXTRAORDINARY GENERAL MEETING OF 27 JUNE 2024 - Availability of preliminary documents
-
Availability of preparatory documents for the annual general meeting of June 13, 2024
-
Safran’s 2024 Annual General Meeting